CORONA in the Saarland
Launched by UNIVERSITÄT DES SAARLANDES · Apr 6, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CORSAAR study, also known as CORONA in the Saarland, is a research project focused on understanding the natural progression of COVID-19. This study aims to learn more about how the virus behaves in people, including those who are experiencing long-term effects known as long-COVID. The study is currently looking for participants of all ages, from newborns to those up to 40 years old, and it welcomes individuals of any gender who have had any form of COVID-19.
If you choose to participate, you will be part of an observational study, meaning researchers will monitor your health and gather information about your experience with COVID-19 over time. There are no specific treatments or interventions involved, so you will continue to receive your usual medical care. Participation may help researchers gain valuable insights into the virus and its impact on health, which could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all form of COVID-19 including long-COVID-19
- Exclusion Criteria:
- • -
About Universität Des Saarlandes
The Universität des Saarlandes is a distinguished academic institution located in Germany, recognized for its commitment to advancing research and education in the medical and health sciences. As a clinical trial sponsor, the university leverages its robust interdisciplinary expertise and state-of-the-art facilities to facilitate innovative research initiatives aimed at addressing critical health challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring rigorous adherence to ethical standards and regulatory compliance throughout the clinical trial process. Through its dedication to scientific excellence and patient-centered research, Universität des Saarlandes plays a vital role in contributing to the development of novel therapeutic interventions and improving healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Homburg, Saarland, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials